[Bencyclan (Fludilat) in the treatment of patients with ischaemic cerebral infarction (author's transl)].
In 50 patients suffering from local cerebral circulation disturbances the effects of bencyclan--administered intravenously in a dosis of 500 mg per day--were evaluated under double-blind conditions. At the same time all patients received digitalis and physiotherapy. Besides a detailed recording of the neurological and psychopathological status a number of psychological tests were applied in order to get objective data about psychomotor function, cerebro-organic capacity and mood. The control recordings after a three weeks' treatment demonstrated an improvement of the clinical as well as the psychological parameters in either group. There were no marked, statistically significant differences in the extent of improvement between the bencyclan and the placebo group; that means bencyclan has no effect on the signs of ischaemic cerebrovascular disease, which exceeds the effects of digitalis and physiotherapy.
D000328:Adult; D000368:Aged; D001537:Bencyclane / Q000494:pharmacology / Q000627:therapeutic use*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003508:Cycloheptanes / Q000627:therapeutic use*; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004341:Drug Evaluation; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D010919:Placebos; D011581:Psychological Tests
D003508:Cycloheptanes; D004071:Digitalis Glycosides; D010919:Placebos; D001537:Bencyclane
Bencyclan (Fludilat) in der Behandlung lokaler Hirndurchblutungsstörungen